Also, largely the largecap stocks are reaching that reasonable valuation phase. There is still a lot of overvaluation in some of the midcap pockets, but I think that also will get corrected over time. So, we are not at the sweet spot as yet where valuations are mouthwatering and it is no brainer to go and buy stocks, but we seem to be getting over there.
Sun Pharma deal structurally strong, debt the only overhang: Amit Khurana
Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma’s acquisition is seen as strategically sound, though debt requires careful management.
April 27, 2026